<HTML><HEAD></HEAD><BODY>MindBranch: &quot;MarketVIEW: Staphylococcus aureus vaccines CAT No: VAMV002 &quot; by VacZine Analytics April 2010 | TradingMarkets.com  New ETF Book by Larry Connors Click here to read more
</br>
 MindBranch: "MarketVIEW: Staphylococcus aureus vaccines CAT No: VAMV002 " by VacZine Analytics April 2010
</br>
Posted on: Tue, 06 Apr 2010 11:51:09 EDT
</br>
 Do you know when to trade  ?Check for a  from TradingMarkets  Apr 06, 2010 M2 PRESSWIRE via COMTEX Staphylococcus aureus S.aureus is an opportunistic pathogen and a major cause of patient morbidity and mortality, especially in "at risk" populations.Prophylatic vaccines could prevent S.aureus infections and become cost effective in achieving savings from expensive infection control interventions e.g.MRSA screening on admission.Although all major companies have now announced S.aureus vaccine programs, Merck & Co Intercell AG are the most advanced Phase II/III .If<b><font color='green'> successful Merck</font></b> & Co Intercell AG are predicted to be first to market in 2013/2014 potentially defining a highly lucrative new market category.This MarketVIEW product gives a comprehensive vaccine value $USD/volume 000s forecast within target nosocomial populations until 2030.The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios.This product is an essential component of any commercial opportunistic assessment focused on nosocomial vaccines.Please note: this is delivered as a Zip file.For full report details visit: http://www.mindbranch.com/products/R3615 28.html CONTACT: Gregg Kellett, Online Marketing Manager, MindBranch Tel: +1 800 298 5699 US Tel: +1 240 747 3093 Int Fax: +1 240 747 3001 e mail: gkellett@marketresearch.com WWW: http://www.mindbranch.com  M2 Communications disclaims all liability for information provided within M2 PressWIRE.Data supplied by named party/parties.Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web.Inquiries to info@m2.com.For full details on Merck & Co MRK .Merck & Co MRK has Short Term PowerRatings at TradingMarkets.Details on Merck & Co MRK Short Term PowerRatings is available at Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day.Join us for our  20 minute tele seminars during the week.Thursday April 29 12:30 PM Hear What Kevin Haggerty Sees in the Stock Market Today!Wednesday April 28 01:00 PM Hear What Gary Kaltbaum Sees in the Stock Market Today!* Attendance is strictly limited and are filled on a first come, first served basis. </br>
</BODY></HTML>